Adherence and growth outcomes in children with growth disorders: results from the Easypod™ Connect Observational Study (ECOS) in Indonesia, Singapore, and Taiwan

Aman Bhakti Pulungan; Fabian Yap; Mei-Chyn Chao; Kah Yin Loke; Chen Yang; Tianrong Ma; Leroy Ovbude; Pen-Hua Su

doi:10.14238/pi62.2.2022.79-85

Aman Bhakti Pulungan Universitas Indonesia, Cipto Mangunkusumo Hospital
Fabian Yap KK Women's and Children's Hospital
Mei-Chyn Chao Kaohsiung Medical University Hospital
Kah Yin Loke National University Hospital
Chen Yang Taipei Medical University Hospital
Tianrong Ma Merck Serono
Leroy Ovbude Business & Decision Life Sciences
Pen-Hua Su Chung Shan Medical University Hospital

DOI: https://doi.org/10.14238/pi62.2.2022.79-85

Keywords: easypod connect; pediatric GH therapy adherence; growth hormone deficiency; small for gestational age; growth outcomes

Abstract

Background Non-objective assessments indicate poor patient adherence to growth hormone (GH) prescribed for growth failure, with sub-optimal growth response. The easypod™ connect device for GH administration enables real-time, objective assessment of adherence.

Objective To examine adherence with pediatric GH therapy in Asia-Pacific countries and relationship with growth outcomes.

Methods Subjects were children in Indonesia, Singapore, Taiwan enrolled in the multi-national, open-label Easypod Connect Observational Study (ECOS). Adherence during follow-up was the
primary endpoint and a relationship with 1-year growth outcomes was assessed by Spearman’s product-moment correlations.

Results Over a 1-year time frame, median overall patient adherence was ?89%; rates were similar for children with GH deficiency (GHD; n=17) and those born small-for-gestational age (SGA; n=5), except that median adherence dropped between 9 months (94%) and 1 year (83%) for SGA subjects. Median initial GH dose was 42.3 ?g/kg/day for GHD subjects and 31.4 ?g/kg/day for SGA subjects. Median age (12 years) and bone age (13 years) indicated that most children had entered puberty at treatment onset. Clinically meaningful improvements in growth were observed at 1 year in the GHD group, but not the SGA group. Statistically significant correlations between adherence and height change (P=0.039) as well as height velocity (P=0.004) were observed.

Conclusions Children in Asia-Pacific countries show high adherence over the first year of GH therapy with easypod. The easypod study also shows that adherence is correlated to good growth outcomes.

References

1. Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86:361-97. DOI: 10.1159/000452150.
2. Navarro R, Dunn JD, Lee PA, Owens GM, Rapaport R. Translating clinical guidelines into practice: the effective and appropriate use of growth hormone. Am J Manag Care. 2013;19(suppl 15):s281-9. PMID: 24494610.
3. Finken MJJ, van der Steen M, Smeets CCJ, Walenkamp MJE, de Bruin C, Hokken-Koelega ACS, et al. Children born small for gestational age: differential diagnosis, molecular genetic evaluation, and implications. Endocr Rev. 2018;39:851-94. DOI: 10.1210/er.2018-00083.
4. Polak M, Blair J, Kotnik P, Pournara E, Pedersen BT, Rohrer TR. Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet® International Outcome Study. Eur J Endocrinol. 2017;177:421-9. DOI: 10.1530/EJE-16-1024.
5. Thomas M, Beckers D, Brachet C, Dotremont H, Lebrethon MC, Lysy P, et al. Adult height after growth hormone treatment at pubertal onset in short adolescents born small for gestational age: results from a Belgian registry-based study. Int J Endocrinol. 2018;2018:6421243. DOI: 10.1155/2018/6421243.
6. Houk CP, Lee PA. Early diagnosis and treatment referral of children born small for gestational age without catch-up growth are critical for optimal growth outcomes. Int J Pediatr Endocrinol. 2012;2012:11. DOI: 10.1186/1687-9856-2012-11.
7. Bakker B, Frane J, Anhalt H, Lippe B, Rosenfeld RG. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab. 2008;93:352-7. DOI: 10.1210/jc.2007-1581.
8. Acerini CL, Wac K, Bang P, Lehwalder D. Optimizing patient management and adherence for children receiving growth hormone. Front Endocrinol (Lausanne). 2017;8:313. DOI: 10.3389/fendo.2017.00313.
9. Devine F, Edwards T, Feldman SR. Barriers to treatment: describing them from a different perspective. Patient Prefer Adherence. 2018;12:129-33. DOI: 10.2147/PPA.S147420.
10. Mohseni S, Heydari Z, Qorbani M, Radfar M. Adherence to growth hormone therapy in children and its potential barriers. J Pediatr Endocrinol Metab. 2018;31:13-20. DOI: 10.1515/jpem-2017-0157.
11. Bagnasco F, Di Iorgi N, Roveda A, Gallizia A, Haupt R, Maghnie M, et al. Prevalence and correlates of adherence in children and adolescents treated with growth hormone: a multicenter Italian study. Endocr Pract. 2017;23:929-41. DOI: 10.4158/EP171786.OR.
12. De Pedro S, Murillo M, Salinas I, Granada ML, Martinez M, Puig-Domingo M, et al. Variability in adherence to rhGH treatment: socioeconomic causes and effect on children's growth. Growth Horm IGF Res. 2016;26:32-5. DOI: 10.1016/j.ghir.2015.12.002.
13. Cutfield WS, Derraik JG, Gunn AJ, Reid K, Delany T, Robinson E, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One. 2011;6:e16223. DOI: 10.1371/journal.pone.0016223.
14. Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr. 2013;79:189-96. DOI: 10.1159/000350251.
15. Weinman J, Ali I, Hodgkinson A, Canfield M, Jackson C. Pilot testing of a brief pre-consultation screener for improving the identification and discussion of medication adherence in routine consultations. Patient Prefer Adherence. 2019;13:1895-8. DOI: 10.2147/PPA.S219860.
16. Bozzola M, Colle M, Halldin-Stenlid M, Larroque S, Zignani M; easypod™ Survey Study Group. Treatment adherence with the easypodâ„¢ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents. BMC Endocr Disord. 2011;11:4. DOI: 10.1186/1472-6823-11-4.
17. Koledova E, Stoyanov G, Ovbude L, Davies PSW. Adherence and long-term growth outcomes: results from the easypod™ connect observational study (ECOS) in paediatric patients with growth disorders. Endocr Connect. 2018;7:914-23. DOI: 10.1530/EC-18-0172.
18. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva, 2006. Available online: https://www.who.int/publications/i/item/924154693X (accessed on 18 January 2022).
19. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child 1966;41:613-35. DOI: 10.1136/adc.41.220.613.
20. Blanco-López A, Antillón-Ferreira C, Saavedra-Castillo E, Barrientos-Pérez M, Rivero-Escalante H, Flores-Caloca O, et al. Adherence to treatment in children with growth hormone deficiency, small for gestational age and Turner syndrome in Mexico: results of the Easypod™ connect observational study (ECOS). J Endocrinol Invest. 2020;43:1447-52. DOI: 10.1007/s40618-020-01218-4.
21. Rodríguez Arnao MD, Rodríguez Sánchez A, Díez López I, Ramírez Fernández J, Bermúdez de la Vega JA, Yeste Fernández D, et al. Adherence and long-term outcomes of growth hormone therapy with easypod™ in pediatric subjects: Spanish ECOS study. Endocr Connect. 2019;8:1240-9. DOI: 10.1530/EC-19-0325.
22. Centonze C, Guzzetti C, Orlando G, Loche S; Italian ECOS Investigators. Adherence to growth hormone (GH) therapy in naïve to treatment GH-deficient children: data of the Italian Cohort from the Easypod Connect Observational Study (ECOS). J Endocrinol Invest. 2019;42:1241-4. DOI: 10.1007/s40618-019-01046-1.
23. Hartmann K, Ittner J, Müller-Rossberg E, Schönau E, Stephan R, Ullrich KP, et al. Growth hormone treatment adherence in prepubertal and pubertal children with different growth disorders. Horm Res Paediatr. 2013;80:1-5. DOI: 10.1159/000351800.
24. Graham S, Weinman J, Auyeung V. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr. 2018;90:221-7. DOI: 10.1159/000493211.
25. Farfel A, Shalitin S, Morag N, Meyerovitch J. Long-term adherence to growth hormone therapy in a large health maintenance organization cohort. Growth Horm IGF Res. 2019;44:1-5. DOI: 10.1016/j.ghir.2018.10.004.
26. Dahlgren J, Veimo D, Johansson L, Bech I. Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: results from an open-label, user survey of everyday use. Curr Med Res Opin. 2007;23:1649-55. DOI: 10.1185/030079907x210589.
27. Straetemans S, Thomas M, Craen M, Rooman R, De Schepper J; BESPEED. Poor growth response during the first year of growth hormone treatment in short prepubertal children with growth hormone deficiency and born small for gestational age: a comparison of different criteria. Int J Pediatr Endocrinol. 2018;2018:9. DOI: 10.1186/s13633-018-0064-3.
28. Bang P, Bjerknes R, Dahlgren J, Dunkel L, Gustafsson J, Juul A, et al. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm Res Paediatr. 2011;75:335-45. DOI: 10.1159/000322878.
29. Loftus J, Lindberg A, Aydin F, Gomez R, Maghnie M, Rooman R, et al. Individualised growth response optimisation (iGRO) tool: an accessible and easy-to-use growth prediction system to enable treatment optimisation for children treated with growth hormone. J Pediatr Endocrinol Metab. 2017;30:1019-26. DOI:10.1515/jpem-2017-0120.
30. Ranke MB, Lindberg A, Mullis PE, Geffner ME, Tanaka T, Cutfield WS, et al. Towards optimal treatment with growth hormone in short children and adolescents: evidence and theses. Horm Res Paediatr. 2013;79:51-67. DOI:10.1159/000347121.